Clinical studies 1993

Sizofiran in ovarian cancer: a prospective RCT of adjuvant immunotherapy

A Japanese RCT of sizofiran (a Schizophyllum commune polysaccharide) as an adjuvant in ovarian cancer: survival on PAC+SPG was significantly higher than on chemotherapy alone in stage Ic–III patients. The benefit appeared at ≥4 cycles; no side effects attributable to SPG.

Inaoka T. et al. Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: a prospective randomized controlled trial. Biotherapy. 1993;7(1):19-23.

Why this study

Sizofiran (SPG, schizophyllan) is a β-glucan from Schizophyllum commune, registered in Japan as a medicinal immunomodulator — not a supplement. Our new "split gill" card is its source species. The question: does adding SPG to chemotherapy improve survival — not just immune markers.

Methods

  • Prospective randomization of 68 ovarian cancer patients.
  • PAC (cisplatin + doxorubicin + cyclophosphamide) ± sizofiran.
  • Endpoint — survival, not surrogates.

Findings

  • In stage Ic–III patients, survival on PAC+SPG was significantly higher than on PAC.
  • The benefit appeared in those receiving ≥4 cycles of PAC+SPG (generalized Kruskal–Wallis p=0.032) and in non-serous adenocarcinomas.
  • No side effects attributable to SPG were recorded.

Limitations

  • n=68 — a small trial; dated 1993 — chemotherapy standards have moved on.
  • Some subgroup analyses sit near the significance threshold (p=0.032–0.076).

Why it matters

The third "Japanese polysaccharide" in our series after lentinan and PSK: SPG is the rare case where a mushroom β-glucan became a licensed drug (in Japan) and has survival data, not only immune parameters.